Effects of rosiglitazone on mRNA expressions of nuclear factor-κB and vascular endothelial growth factor in Hep-2 cells

Aim:By detecting nuclear factor-κB(NF-κB)and vascular endothelial growth factor(VEGF) expression changes in human laryngeal carcinoma Hep-2 cells before and after being treated with rosiglitazone(ROS),to explore its role in Hep-2 proliferation inhibition.Methods:MTT method was used to observe the proliferation of Hep-2 cells treated with 12.5,25.0,50.0,and 100.0 μmol/L ROS for 12,24,36,48,60,and 72 hours.RT-PCR method was used to detect the expressions of NF-κB and VEGF mRNA in the Hep-2 cells treated with ROS at 50 μmol/L for 0,24,48,and 72 hours.Results:ROS inhibited growth of Hep-2 cells in a dose-dependent(at 12,24,36,48,60,and 72 h each concentration group,F were 117.584,98.241,92.352,117.228,148.458,and 124.900,P0.001) and time-dependent manner(12.5,25.0,50.0,and 100.0 μmol/L groups at different time point,F were 140.949,123.335,148.325,and 176.590,P0.001).The expression of NF-κB mRNA was(0.854±0.066),(0.653±0.059),(0.489±0.027),and(0.336±0.031) at 0,24,48,and 72 h after the treatment by ROS at 50 μmol/L,and there was significant difference among different time groups(F=111.357,P0.001).The expression of VEGF mRNA was(0.756±0.057),(0.628±0.039),(0.482±0.044),and(0.318±0.035) at 0,24,48,and 72 h,and there was significant difference among different time groups(F=89.796,P0.001).Conclusion:ROS could inhibit Hep-2 cell proliferation,and its mechanism is related to down-regulating NF-κB and VEGF mRNA expression.